Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Transplant Rev (Orlando). 2019 May 13;33(3):130–136. doi: 10.1016/j.trre.2019.05.001

Table 5.

Questions posed by DCreg therapy

Manufacturing (choice of agents(s) to confer tolerogenicity)
Cell dosage
Timing/frequency of cell infusion
Relevance of Ag pulsing
Migratory abilities and relevance (depending on the site of administration)
Longevity; fate of donor MHC gene products
Potential reprogramming under inflammatory conditions
‘Appropriate’ immunosuppressive agents/regimen
Overcoming immunologic memory
Comparison with other types of regulatory immune cell therapy (e.g. Treg)
Cost